Beam Therapeutics Inc. (BEAM) Financial Statements (2024 and earlier)

Company Profile

Business Address 26 LANDSDOWNE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,100,0001,100,0001,100,0001,100,0001,200,0001,200,000
Cash and cash equivalents225,544249,771232,767156,511265,623296,821
Short-term investments847,472809,700    
Other undisclosed cash, cash equivalents, and short-term investments26,98440,529867,233943,489934,377903,179
Other undisclosed current assets(5,195)(16,969)(7,104)8,912(20,110)39,484
Total current assets:1,094,8051,083,0311,092,8961,108,9121,179,8901,239,484
Noncurrent Assets
Operating lease, right-of-use asset114,075116,159118,513115,534117,426105,543
Property, plant and equipment128,203121,822115,620111,180106,09094,288
Restricted cash and investments15,4229,80212,75412,75012,74612,746
Other noncurrent assets1,3821,5381,9311,8742,2231,341
Total noncurrent assets:259,082249,321248,818241,338238,485213,918
TOTAL ASSETS:1,353,8871,332,3521,341,7141,350,2501,418,3751,453,402
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities31,58737,89547,16447,66438,77421,484
Employee-related liabilities12,0048,9496,771
Accounts payable6,88614,0639,0297,0247,0956,266
Accrued liabilities24,70123,83238,13528,63622,7308,447
Deferred revenue139,127142,737135,974159,902139,666115,049
Debt9121,4211,8532,2102,3892,337
Derivative instruments and hedges, liabilities13,60012,70018,30021,30016,40028,600
Other undisclosed current liabilities24,31025,17220,3047,78315,04951,328
Total current liabilities:209,536219,925223,595238,859212,278218,798
Noncurrent Liabilities
Long-term debt and lease obligation8759831,154166,463165,772138,438
Finance lease, liability8759831,1541,3881,7872,404
Liabilities, other than long-term debt331,833349,938383,491230,451240,164267,098
Deferred revenue156,202171,708202,179198,288208,824225,093
Other liabilities1,19217322425330511,090
Operating lease, liability163,851165,298168,625165,075163,985136,034
Business combination, contingent consideration, liability10,58812,75912,46331,91031,03530,915
Total noncurrent liabilities:332,708350,921384,645396,914405,936405,536
Total liabilities:542,244570,846608,240635,773618,214624,334
Equity
Equity, attributable to parent811,643761,506733,474714,477800,161829,068
Common stock780744712705703698
Additional paid in capital2,049,4761,915,3491,792,5541,737,4591,713,0861,668,567
Accumulated other comprehensive loss(2,015)(765)(2,430)(4,674)(4,190)(2,709)
Accumulated deficit(1,236,598)(1,153,822)(1,057,362)(1,019,013)(909,438)(837,488)
Total equity:811,643761,506733,474714,477800,161829,068
TOTAL LIABILITIES AND EQUITY:1,353,8871,332,3521,341,7141,350,2501,418,3751,453,402

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues20,11624,20820,03715,79916,6528,432
Gross profit:20,11624,20820,03715,79916,6528,432
Operating expenses(122,264)(123,136)(109,022)(107,102)(98,618)(84,657)
Operating loss:(102,148)(98,928)(88,985)(91,303)(81,966)(76,225)
Nonoperating income19,3722,46851,6369,63810,0167,011
Investment income, nonoperating  6,9325,102  390
Loss from continuing operations before income taxes:(82,776)(96,460)(37,349)(81,665)(71,950)(69,214)
Income tax expense   (1,000)(2,410)  
Loss from continuing operations:(82,776)(96,460)(38,349)(84,075)(71,950)(69,214)
Loss before gain (loss) on sale of properties:(84,075)(71,950)(69,214)
Net loss:(82,776)(96,460)(38,349)(84,075)(71,950)(69,214)
Other undisclosed net loss attributable to parent    (25,500)  
Net loss available to common stockholders, diluted:(82,776)(96,460)(38,349)(109,575)(71,950)(69,214)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(82,776)(96,460)(38,349)(84,075)(71,950)(69,214)
Comprehensive loss:(82,776)(96,460)(38,349)(84,075)(71,950)(69,214)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,250)1,6652,244(25,984)(1,481)(2,659)
Comprehensive loss, net of tax, attributable to parent:(84,026)(94,795)(36,105)(110,059)(73,431)(71,873)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: